Study of the value of drug tadalafil on improvement in effort tolerance in patients of chronic lung diseases.
Phase 3
Completed
- Conditions
- Health Condition 1: null- Chronic pulmonary disease patients with pulmonary arterial hypertension (PAH).
- Registration Number
- CTRI/2015/01/005413
- Lead Sponsor
- il
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 100
Inclusion Criteria
1.Adult males or females with a diagnosis of
chronic pulmonary disease with PAH.
2.Patients between 20 to 80 years of age.
3.Willingness to participate in the study.
Exclusion Criteria
1.History or clinical evidence of chronic
pulmonary diseases without PAH.
2.Patients of Coronary artery disease,
chronic kidney disease, liver disease,
Left ventricular failure.
3.Patients with myopathy/muscular dystrophy
4.Patients with Peripheral vascular
disease/Osteoarthritis of Knees
5.Pregnancy
6.Patients aged less than 20 years and more
than 80 years
7.Drug history of Anorexigens
8.Patients with HIV
9.Patient unwilling to participate in the
study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method â?¢To study the effect of tadalafil on 6-minute walk distance in chronic pulmonary disease patients with pulmonary arterial hypertension.Timepoint: primary outcome parameters was reassessed after three months
- Secondary Outcome Measures
Name Time Method â?¢To study the effect of tadalafil on; <br/ ><br>oRV Function, PVR, PAH and arterial blood gases. <br/ ><br>oAssociation of 6-minute walk distance with indices of cardio- pulmonary haemodynamics, pulmonary function and arterial oxygen saturation. <br/ ><br>oQuality of Life. <br/ ><br>Timepoint: Reassessment of variable cardiopulmonary haemodynamic parameters and quality of life was done after three months.